Accessibility Menu
Charles River Laboratories International Stock Quote

Charles River Laboratories International (NYSE: CRL)

$188.26
(2.2%)
+4.12
Price as of October 21, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$188.26
Daily Change
(2.2%) +$4.12
Day's Range
$184.99 - $190.41
Previous Close
$188.26
Open
$185
Beta
1.26
Volume
1,049,335
Average Volume
943,696
Market Cap
9.1B
Market Cap / Employee
$184.14M
52wk Range
$91.86 - $230.02
Revenue
-
Gross Margin
0.30%
Dividend Yield
N/A
EPS
-$1.32
CAPs Rating
-
Industry
Life Sciences Tools and Services

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Charles River Laboratories International Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
CRL-3.48%-19.52%-4.25%+737%
S&P+15.06%+95.03%+14.29%+367%

Charles River Laboratories International Company Info

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The Research Models and Services segment consists of the commercial production and sale of research models, research products, and the provision of services related to the maintenance and monitoring of research models and the management of the clients’ research operations. The Discovery and Safety Assessment segment offers integrated drug discovery services directed at the identification, screening, and selection of a lead compound for drug development and offers safety assessment services, including bioanalysis, drug metabolism, pharmacokinetics, toxicology, and pathology. The Manufacturing Support segment consists of Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services, Biologics Solutions, which performs specialized testing of biologics as well as contract development and manufacturing, and Avian Vaccine Services, which supplies specific-pathogen-free chicken eggs and chickens. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$1.03B0.6%
Gross Profit$318.16M-5.2%
Gross Margin30.83%-1.9%
Market Cap$7.45B-30.0%
Market Cap / Employee$0.37M0.0%
Employees20.1K-7.8%
Net Income$52.69M-44.1%
EBITDA$251.84M-1.5%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$183.22M2.1%
Accounts Receivable$767.57M0.7%
Inventory279.6-19.9%

Liabilities

Q2 2025YOY Change
Long Term Debt$2.79B-1.8%
Short Term Debt$2.93M-8.7%

Ratios

Q2 2025YOY Change
Return On Assets-0.89%-6.5%
Return On Invested Capital6.23%-1.4%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$169.31M9.9%
Operating Free Cash Flow$204.60M5.7%

Valuation

MetricQ1 2024Q2 2024Q3 2024Q4 2024YoY Change
Price to Earnings31.4724.4224.49725.772726.88%
Price to Book2.732.502.222.33-20.19%
Price to Sales2.522.351.971.84-30.08%
Price to Tangible Book Value-64.71-78.15-70.94-22.26-46.14%
Price to Free Cash Flow TTM18.2518.9814.0412.79-41.86%
Enterprise Value to EBITDA54.2360.5648.9639.91-23.98%
Free Cash Flow Yield5.5%5.3%7.1%7.8%72.00%
Return on Equity11.8%0.5%-0.9%-2.0%-115.60%
Total Debt$2.76B$2.78B$2.99B$2.79B-1.84%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.